• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    4/17/23 1:31:26 PM ET
    $ALLR
    $BIMI
    $BLCM
    $BNGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • ContraFect (NASDAQ:CFRX) stock rose 317.8% to $3.76 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 93.7 million shares, making up 12124.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.8 million.
    • Windtree Therapeutics (NASDAQ:WINT) shares rose 168.54% to $11.76. Trading volume for this security as of 13:30 EST is 9.3 million, which is 6427.0% of its average full-day volume over the last 100 days. The company's market cap stands at $10.6 million.
    • Bellicum Pharmaceuticals (NASDAQ:BLCM) stock increased by 113.44% to $0.6. Bellicum Pharmaceuticals's stock is trading at a volume of 43.9 million shares as of 13:30 EST. This is 42089.8% of its average full-day volume over the last 100 days. The company's market cap stands at $5.4 million.
    • Prometheus Biosciences (NASDAQ:RXDX) stock rose 69.33% to $193.06. As of 13:30 EST, this security is trading at a volume of 11.6 million shares, making up 2436.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.1 billion.
    • Satsuma Pharma (NASDAQ:STSA) stock increased by 66.41% to $1.09. Trading volume for Satsuma Pharma's stock is 40.8 million as of 13:30 EST. This is 26316.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $36.1 million.
    • Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 33.33% to $3.6. Reshape Lifesciences's stock is trading at a volume of 2.0 million shares as of 13:30 EST. This is 286.1% of its average full-day volume over the last 100 days. The company's market cap stands at $6.4 million.

    Losers

    • Pear Therapeutics (NASDAQ:PEAR) shares fell 29.0% to $0.05 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 36.5 million shares, making up 518.1% of its average full-day volume over the last 100 days. The company's market cap stands at $7.2 million.
    • Predictive Oncology (NASDAQ:POAI) shares declined by 24.51% to $0.29. As of 13:30 EST, Predictive Oncology's stock is trading at a volume of 5.0 million, which is 363.2% of its average full-day volume over the last 100 days. The company's market cap stands at $22.7 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares declined by 18.75% to $1.17. The current volume of 2.3 million shares is 461.2% of Allarity Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.1 million.
    • BIMI Intl Medical (NASDAQ:BIMI) stock fell 18.24% to $0.59. Trading volume for this security as of 13:30 EST is 255.9K, which is 370.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.2 million.
    • Bionano Genomics (NASDAQ:BNGO) stock declined by 16.37% to $0.91. As of 13:30 EST, Bionano Genomics's stock is trading at a volume of 22.0 million, which is 365.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $279.1 million.
    • Creative Medical Tech (NASDAQ:CELZ) shares decreased by 13.92% to $0.61. As of 13:30 EST, this security is trading at a volume of 813.6K shares, making up 20.2% of its average full-day volume over the last 100 days. The company's market cap stands at $8.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $BIMI
    $BLCM
    $BNGO

    CompanyDatePrice TargetRatingAnalyst
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Bionano Genomics Inc.
    $BNGO
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    Bionano Genomics Inc.
    $BNGO
    9/10/2024Buy → Neutral
    BTIG Research
    Predictive Oncology Inc.
    $POAI
    8/19/2024$3.00Buy
    H.C. Wainwright
    Prometheus Biosciences Inc.
    $RXDX
    5/10/2023$160.00 → $200.00Buy → Hold
    Jefferies
    Bionano Genomics Inc.
    $BNGO
    1/5/2023$4.00Sector Outperform
    Scotiabank
    Bionano Genomics Inc.
    $BNGO
    12/12/2022$3.50Buy
    BTIG Research
    Satsuma Pharmaceuticals Inc.
    $STSA
    10/10/2022$15.00Mkt Perform → Outperform
    SVB Leerink
    More analyst ratings

    $ALLR
    $BIMI
    $BLCM
    $BNGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 18 shares, decreasing direct ownership by 3% to 644 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:31:45 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 3 shares, decreasing direct ownership by 1% to 260 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:29:36 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 6 shares, decreasing direct ownership by 2% to 263 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    2/18/26 4:28:24 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ALLR
    $BIMI
    $BLCM
    $BNGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

    4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

    10/9/24 7:46:52 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fraser Craig bought $2,550 worth of shares (2,500 units at $1.02), increasing direct ownership by 5% to 57,877 units (SEC Form 4)

    4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

    9/28/23 7:24:59 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fraser Craig bought $2,250 worth of shares (2,500 units at $0.90), increasing direct ownership by 5% to 55,377 units (SEC Form 4)

    4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

    9/27/23 7:34:59 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $BIMI
    $BLCM
    $BNGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

    SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ:BNGO) participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. Twelve studies, representing a two-fold increase over the number of studies in 2025, were presented as either oral (4) or poster presentations (8). The studies illustrated how optical genome mapping (OGM) can drive discoveries in genomics by detecting structural variants (SVs) that may be missed by other techniques across cancer genomics, such as hematologic malignancies, and constitutional genetic disorders, including rare diseases and reproductive disorders. Additionally, the

    3/17/26 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.biona

    3/9/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

             Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured as Non-Convertible Debt Financing TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Com

    3/6/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIMI
    $BLCM
    $BNGO
    SEC Filings

    View All

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    3/9/26 9:02:24 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    3/6/26 8:22:50 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    2/19/26 8:00:48 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIMI
    $BLCM
    $BNGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Allarity Therapeutics with a new price target

    Ascendiant Capital Markets initiated coverage of Allarity Therapeutics with a rating of Buy and set a new price target of $9.00

    7/28/25 8:53:33 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bionano Genomics downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral

    11/15/24 7:40:01 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics downgraded by BTIG Research

    BTIG Research downgraded Bionano Genomics from Buy to Neutral

    9/10/24 7:37:53 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ALLR
    $BIMI
    $BLCM
    $BNGO
    Financials

    Live finance-specific insights

    View All

    Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.biona

    3/9/26 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates

    Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues) Windtree would receive a payment of $700,000 from Seismic Pharmaceutical Holdings contingent on a financing round resulting in gross cash proceeds of at least $10,000,000 Additionally, Windtree transfers certain cardiovascular development payables to Seismic Pharmaceutical Holdings WARRINGTON, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (OTCID: WINT), a diversified company with several divisions and focused on becoming

    12/23/25 9:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

    PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of lo

    11/14/25 5:12:46 PM ET
    $POAI
    Industrial Specialties
    Health Care

    $ALLR
    $BIMI
    $BLCM
    $BNGO
    Leadership Updates

    Live Leadership Updates

    View All

    Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale

    SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA™ software. Other talks covered topics like Bionano's Ionic® system for isolating DNA and RNA for next generation sequencing (NGS) and advanced analytical tools that could be the future of digital cytogenetics

    2/27/26 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

    Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of

    10/14/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Vyome Announces New Board of Directors with Deep MIT and AI Ties

    Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ:RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND. The new Vyome board members, which include four Massachusetts Institute of Technology (MIT) alums, are all persons with prior

    8/12/25 9:48:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    $ALLR
    $BIMI
    $BLCM
    $BNGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

    SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 7:15:44 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Windtree Therapeutics Inc.

    SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 3:40:27 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

    SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 8:53:39 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care